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Operator exposureDermal absorption is a key parameter in non-dietary human safety assessments for agrochemicals.
Conservative default values and other criteria in the EFSA guidance have substantially increased genera-
tion of product-speciﬁc in vitro data and in some cases, in vivo data. Therefore, data from 190 GLP- and
OECD guideline-compliant human in vitro dermal absorption studies were published, suggesting EFSA
defaults and criteria should be revised (Aggarwal et al., 2014). This follow-up article presents data from
an additional 171 studies and also the combined dataset. Collectively, the data provide consistent and
compelling evidence for revision of EFSA’s guidance. This assessment covers 152 agrochemicals, 19
formulation types and representative ranges of spray concentrations. The analysis used EFSA’s worst-case
dermal absorption deﬁnition (i.e., an entire skin residue, except for surface layers of stratum corneum, is
absorbed). It conﬁrmed previously proposed default values of 6% for liquid and 2% for solid concentrates,
irrespective of active substance loading, and 30% for all spray dilutions, irrespective of formulation type.
For concentrates, absorption from solvent-based formulations provided reliable read-across for other
formulation types, as did water-based products for solid concentrates. The combined dataset conﬁrmed
that absorption does not increase linearly beyond a 5-fold increase in dilution. Finally, despite using
EFSA’s worst-case deﬁnition for absorption, a rationale for routinely excluding the entire stratum corneum
residue, and ideally the entire epidermal residue in in vitro studies, is presented.
 2015 Elsevier Inc. All rights reserved.1. Introduction layer is the non-vascular epidermis, from which chemicals cannotThe current authors published a paper based on an in vitro
human dermal absorption dataset collected up to 2012
(Aggarwal et al., 2014). This paper provides a new dataset of
studies performed mainly between 2012 and February 2014; the
combined dataset is also presented and evaluated.
1.1. Background
Skin is a multi-layered organ that forms a natural barrier to
absorption of exogenous substances, including chemicals. Its upperbe absorbed per se. In addition, the epidermis divides and grows in
an outward direction whereby retained residues are eliminated via
normal epidermal desquamation (Aggarwal et al., 2014; Maibach
and Patrick, 2001; WHO, 2006a).
Dermal absorption is a key parameter used in human
(operators, bystanders, residents and re-entry workers) exposure
risk assessments for agrochemicals in Europe. Exposure models
are used to estimate the external skin dose and dermal absorption
values are used to convert them into systemic (internal) exposures,
which are then compared to reference doses (e.g., Acceptable
Operator Exposure Level – AOEL).
In a typical OECD test guideline-compliant dermal absorption
study (OECD 428) at least 4 skin replicates (in the case of current
datasets, from at least two donors) are exposed to the undiluted
formulation (concentrate) and one or more spray dilutions for
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measured for 24 h to match with reference dose and estimated
exposure units. Dermal absorption studies preferentially use
human skin, in vitro; rat skin can also be used, notably to allow
bridging to in vivo studies in rats. Rat skin is anatomically signiﬁ-
cantly different (thinner stratum corneum, more hair follicles, etc.)
to human skin and typically much more permeable to chemicals,
so it represents a worst-case model for human skin (Bronaugh
et al., 1982; Chan et al., 2010; van Ravenzwaay and Leibold, 2004).
When all three studies are performed the differences between
human and rat skin can be mitigated by correcting the penetration
observed in rats in vivo by a factor experimentally determined from
human and rat skin in vitro in a so-called ‘triple pack’ approach.
More recently, EFSA published a scientiﬁc opinion (EFSA, 2011)
and guidance (EFSA GD, 2012) on dermal absorption. Similar guid-
ance has also been published by OECD (OECD guidance note 156).
While OECD (Guidelines 427, 428 and Guidance 28) explain how to
conduct these studies, the subsequent EFSA (and OECD) guidance
introduced secondary standards and different criteria for cal-
culation of dermal absorption, including:
 high default values:
o concentrate 25% (75% if active substance content is <5%)
o spray dilution 75%
 no bridging from one formulation to another containing the
same active substance if:
o any formulation constituent differs by ±25%
o skin irritation and skin sensitisation properties differ
 linear extrapolation, or use of a default value, if a tested con-
centration is higher than a label spray dilution
 assuming the skin residue (except some or all of the stratum
corneum) at the end of a study has been absorbed
 normalising a mean if recovery is <95% (versus <90% in all
other OECD studies)
 adding a standard deviation to a mean when it’s > 25% of a
mean (unique for OECD-compliant studies).
The EFSA GD triggers the requirement for dermal absorption
studies for almost all formulations (including virtually identical
formulations of the same active substance) even when expert
judgement indicates that reliable surrogate data are already
available.
To investigate the reliability of EFSA guidance, the authors
initiated a project to collect, collate and systematically analyse
all available dermal absorption data derived from in vitro studies
using human skin, which is the preferred method in EU data
requirements (EC 1107/2009; EC 284/2013EC).
Dermal absorption values in this analysis were calculated using
EFSA’s worst-case assumption that the whole skin residue (except
tape strips 1 and 2) is absorbed. Previously, a dataset of 190 OECD
GLP and test guideline-compliant in vitro human skin studies were
published (Aggarwal et al., 2014). In this assessment, a further 171
studies (referred to as the ‘new dataset’) were collected and evalu-
ated. The new dataset was then combined with the previous data-
set (referred to as the ‘combined dataset’) and assessments were
made on both the new and the combined dataset.1.2. Summary of the previous data evaluation
The previous assessment (Aggarwal et al., 2014) of 190 in vitro
human-skin dermal absorption studies using EFSA’s worst-case
deﬁnition of dermal absorption and 95th percentile absorption
values – to match EFSA’s proposal to use 75th or 95th percentile
exposure data distributions for chronic or acute risk assessments,
respectively – supported: dermal absorption default values of 6% for liquid and 2% for solid
concentrates, irrespective of the active substance concentration
 dermal absorption default values of 30% for all spray dilutions,
irrespective of the formulation type
 dermal absorption values for solvent-based formulations to be
conservative read-across data for water-based and solid
formulations
 dermal absorption does not increase linearly with dilution; a
proposal was made for no adjustment when dilution increased
by less that 2-fold, and a linear increase for a 2- to 5-fold
increase in dilution up to a default value of 30%.
1.3. Objectives
The current publication investigates the validity of earlier con-
clusions (Aggarwal et al., 2014) by providing a new dataset of 171
studies and a combined dataset of 295 in vitro human dermal
absorption studies.2. Methods
2.1. Selection of studies
All availableGLP andOECD428-compliant in vitrohumandermal
absorption studies,mostly performedbetween2012 and2014,were
collected (OECD, 1997;OECD428, 2004). This comprised171 studies
and provided 182 dermal absorption values for concentrates and
277 for spray dilutions. The resulting dataset was then combined
with the published dataset (Aggarwal et al., 2014). To ensure
homogeneity of the dataset, the following type of studies were
excluded from thenewdataset, and also from the combineddataset:
 studies with exposure duration exceeding 10 h
 studies with an experimental duration exceeding 24 h
 studies where values for tape strips 1 and 2 were not available
 studies with added surfactants or adjuvants (i.e., that were not
components of the agrochemical formulation).
Since these studies are OECD test guideline and GLP compliant,
adjustments for recovery (where <95%) or additions of standard
deviations (where >25% of mean) required by the EFSA GD were
not made as they are considered to represent unacceptable reg-
ulatory conservatism as opposed to scientiﬁcally substantiated
and deﬁned criteria.
Further, upon assessing the previous dataset two errors were
identiﬁed: (1) one dermal absorption estimate was mistakenly
excluded from the evaluation because of a presumably negative
dermal absorption value; this value was re-calculated and incorpo-
rated into the combined assessment, and (2) four values derived
using an added external surfactant were included in the previous
evaluation; these values were excluded from the combined assess-
ment. However, these changes do not affect the overall conclusions
previous published by Aggarwal et al. (2014).
This assessment comprises studies covering 19 different
formulation types (Table 1) and 152 different active substances.
The concentration range of the active substances in the formula-
tions was 0.061 to 853.0 g/L for the concentrates and 0.00075 g/L
to 187.5 g/L for dilutions. The active substances had a wide range
of octanol–water partition coefﬁcients (LogPow; 3.2 to 9.085)
and molecular weights (169 to 1632.525 g/mol).
2.2. Data analysis
EFSA Guidance (2012) provides decision logic for assessors to
determine the extent to which pesticide residue in the stratum
Table 1
Grouping of formulation types and codes used in this study (WHO, 2006b).
Grouping of
formulation types
Formulation
Code
Number of
studies
Description
Primarily organic
solvent-based
EC 65 Emulsiﬁable concentrate
EW 10 Emulsion, oil in water
SE 25 Suspo-emulsion
Primarily water-
based/dispersed
SL 15 Soluble concentrate
SC 90 Suspension concentrate
OD 16 Oil-based suspension
concentrate
FS 14 Flowable concentrate for
seed treatment
Solids WP 7 Wettable powder
WG 36 Water dispersible
granules
SG 4 Water soluble granules
Other types CB 1 Bait concentrate
CS 1 Capsule suspension
DS 1 Powder for dry seed
treatment
ES 1 Emulsion for seed
treatment
GEL 2 Gel
ME 2 Micro-emulsion
OF 1 Oil-miscible ﬂowable
concentrate
RB 3 Bait block
ZC 3 CS and SC mixture
Fig. 1. Dermal absorption of concentrates (A, B) and spray dilutions (C, D) of the new da
95th percentiles (hollow square). The hollow upside-down triangles depict values that
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EFSA guidance occasionally allows exclusion of all tape-strip resi-
dues from the calculation of absorbed dose, this current analysis
is based on EFSA’s worst-case assumption that all tape strips
(except 1 and 2) are absorbed: Dermal absorption =
[Radioactivity present in receptor ﬂuid + receptor chamber
wash + whole skin sample]  [radioactivity in the ﬁrst two tape
strips]. From the individual studies, group mean values for concen-
trates and spray dilutions were calculated.
2.3. Data evaluation
The data were evaluated to determine default values and to
assess a potential relationship between dermal absorption and
physical properties of the formulation groups (liquids versus
solids), formulation type, concentration, dilution factor, MW or
logPow of the active substance. Dermal absorption values are
plotted individually and/or as boxplots for both concentrates and
dilutions. Individual values are presented as ‘dot-plots’ and to
avoid excessive overlapping of individual values (dots) they are
presented with an extended lateral perspective (Fig. 1A and C).
Boxplots show the minimum value, 25th percentile (lower end of
the box), median (horizontal line within the box), 75th percentile
(upper end of the box) and maximum value. Additionally, the
95th-percentile of a distribution is superimposed as a hollow
square symbol. Data values exceeding 1.5-times the interquartile
range are presented as dots. In all ﬁgures, ‘open’ and ‘solid’ box-
plots represent the analysis of new and combined datasets,
respectively.taset by physical state, either by scatter (A, C) or boxplot (B, D) with superimposed
have been excluded from the evaluation (Section 3.1).
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type and dilution to assess the impact of these parameters. To
investigate how initial physical form inﬂuenced dermal absorption,
the data were further grouped for solid and liquid concentrates.
Spray dilutions from solid and liquid concentrates are denoted as
‘solid’ and ‘liquid’ dilutions, respectively, even though the true
physical form of all dilutions is of course liquid. To investigate
how the formulation matrix (i.e., formulation type) inﬂuenced
dermal absorption of a concentrate, values were grouped into pri-
marily organic-solvent base (‘‘EC + EW + SE’’), primarily water-
based/dispersed (‘‘SL + SC + OD + FS’’), or solid (‘‘WP + WG + SG’’)
formulations.2.4. Values excluded from the evaluation
Some dermal absorption values in the new dataset were
excluded from evaluations. The individual values are included
and are depicted as up-side down triangles in Fig. 1; reasons for
exclusion are explained in Section 3.1.2.5. Statistical analysis and software
Data were extracted from study reports and summarised in
stacked spreadsheet format (Microsoft Excel 2010, Redmond,
WA, USA). The absorption values were calculated as described in
Section 2.2. The spreadsheet was saved as a comma-separated
values-ﬁle and read into the statistical programming language R
(version 3.0.0 (2013-04-03), R Core Team, 2014). Graphs were cre-
ated with ggplot2 (version 0.9.3.1, Wickham, 2009). Medians and
percentiles (25th, 75th and 95th) were calculated with the R
Stats Package (version 3.0.0). For null hypothesis statistical signiﬁ-
cance testing, alpha was set at a = 0.01 and statistical signiﬁcance
was assumed when p was less than a.
The data did not appear to be normally distributed, as investi-
gated by Q-Q (quantile–quantile) plots. Therefore, the data were
log-transformed before further statistical analysis was conducted,
which resulted in near-normality. The inﬂuence of formulation
type groupings (organic-solvent based versus primarily water
based versus solids) on dermal absorption was investigated by
ANOVA, i.e., to investigate read-across possibilities.
Homoscedasticity, similar variances of the groups as one of the
assumption of ANOVA, was checked with Levene’s test. Post hoc
comparisons were conducted with Tukey’s Honestly Signiﬁcant
Difference (HSD) test.Table 2
Summary of new and combine datasets.
Number of studiesa Number of values
New dataset
Total Collected 171 464
Excluded 5
Evaluated 459
Concentrates Solid 30 34
Liquid 132 148
Dilutions All types 161 277
Combined datasetb
Totalc Collected 295 762
Excluded 13
Evaluated 749
Concentrates Solid 47 53
Liquid 232 250
Dilutions All types 280 446
a Several studies comprised values for multiple active substances or formulation type
b Combined dataset is combination of the new dataset and the dataset published in A
c The number of studies from the old dataset added to the combined dataset differs f3. Results
The current publication aims to verify and thereby strengthen
previous conclusions (Aggarwal et al., 2014) by expanding the
dataset by addition of newly available dermal absorption studies
mostly performed between 2012 and 2014 (‘new dataset’). The
current analysis is based on 295 in vitro human dermal absorption
studies in total (‘combined dataset’).3.1. Strength of dataset and exclusion of outliers
Unlike the EFSA dataset, the datasets used in this evaluation are
homogeneous, being derived from a single study type (i.e., in vitro
human) which is also the preferred test method in the EU reg-
ulation for plant protection products (EC 1107/2009; EC 284/
2013EC). A single worst-case EFSA deﬁnition of dermal absorption
was used in all endpoint evaluations. The combined dataset is
robust and representative of most if not all plant protection prod-
ucts (PPP) as it includes 295 studies for 152 active substances from
19 formulation types, and a wide range of chemistry (LogPow, MW,
water solubility, etc.) and concentrations (Section 2.1).
As presented in Fig. 1A and C (as inverted triangles), a tiny
minority (5, or 1.1%, Table 2) of the dermal absorption values were
considered to be outliers and were excluded from further analysis.
The rationales used to identify values as outliers were as follows.
One study with an SC formulation reported dermal absorption
values of 19, 20 and 7% for the concentrate, 1:40 and 1:200 dilu-
tions, respectively. For an SC concentrate, 19% is remarkably high
and unrepresentative (7% was the maximum value among 89 SC
formulations, Fig. 4B). Furthermore, dermal absorption from the
concentrate was similar or higher than from the dilutions, and
there was no increase in absorption with dilution for the sprays.
Dermal absorption for the same active substance in other two
formulations with comparable concentrations of the excluded con-
centrate value was below 1% (Fig. 1A and C).
In a second study, dermal absorption for the concentrate
(13.6%) was derived by testing the solid (WP) in a 1:19 dilution
(Fig. 1A). However, a 1:19 dilution is not representative of a con-
centrate (or a spray dilution of this formulation).
In a third study, water permeability coefﬁcients (Kp) were high,
indicating that skin integrity had been compromised. Moreover,
when similar concentrations of the concentrate or spray dilution
were tested with other formulations with acceptable Kp the
dermal absorption values were signiﬁcantly lower and, when the% Dermal absorption
95th percentile 75th percentile Median 25th percentile
1.5 0.7 0.3 0.1
4.9 1.3 0.6 0.3
33.3 16.0 6.4 2.9
1.6 0.7 0.3 0.1
5.2 1.3 0.6 0.3
31.9 15.5 6.7 3.1
s.
ggarwal et al., 2014.
rom the previous publication, see Sections 2.1 and 3.1.
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approach, absorption was lower still (Fig. 1C).
In the fourth study, absorption of a concentrate into the
receptor ﬂuid was 0.5% and the skin, excluding stratum corneum,
contained 0.5% but 77% was in the stratum corneum (Fig. 1A). The
remarkably high stratum corneum residue was considered to reﬂect
inefﬁcient skin washing as evidenced by three other studies con-
ducted at the same time, in the same laboratory with same active
substance where the stratum corneum residue was <2%.
For these reasons, these ﬁve values (4 concentrate and 1
dilution) were excluded from further analysis.
There were other dermal absorption values that appeared
unrepresentative of the whole dataset but a robust justiﬁcation
for exclusion could not be established and so they were included
in endpoint evaluations; these are discussed below for
information.
In one study, spray dilutions had dermal absorption values of 59
and 62% (Fig. 1C). However, values for the same active substance
tested in four other studies in the same laboratory, with the same
experimental protocol at comparable dilutions were all approxi-
mately 20%. In all of the studies, the skin residue was <1% and
the concentrates had similar dermal absorption values below 3%.
In a similar case, dermal absorption of an active substance from
50- and 200-fold dilutions of an EC formulation was 34% and
44%, respectively (Fig. 1C). However, dermal absorption was 4–
12% from 6 other spray dilutions for the same concentrations of
the active substance. In a third study, dermal absorption was 9%
and 36% for the concentrate and dilution, respectively (Fig. 1A
and C). However, absorption into the receptor ﬂuid was very low
(only 0.4% and 2.8%) with large amounts (13% and 44%) present
in the skin, of which 60–70% was in the stratum corneum. Since
the active substance is highly lipophilic, high skin residue is
expected (ECETOC, 1993). The high ‘dermal absorption’ values
reﬂect the assumption that the whole skin residue is considered
absorbable, which it is not.3.2. Effect of physical form on dermal absorption and default values
3.2.1. New dataset
Median, 75th and 95th percentile dermal absorption values
were 0.7, 1.3 and 4.9% for liquid concentrates and 0.3, 0.7, and
1.5% for solid concentrates (Fig. 1B, Table 2). Dermal absorption
from liquid concentrates was higher compared to solid concen-
trates, especially at the 95th percentile, therefore, different
defaults for liquids and solids are proposed.Fig. 2. Dermal absorption boxplots of concentrates (A) and spray dilutions (B) of the
percentiles (hollow square).Median, 75th and 95th percentile values were 7.1, 16.2 and
31.7%, and 4.1, 6.9 and 25.0% from spray dilutions of liquid and
solid formulations, respectively (Fig. 1D, Table 2). Since the differ-
ence in dermal absorption from both types of spray dilutions was
small, a single default was proposed and median and percentile
values for all spray dilutions combined were calculated (group
‘‘All’’ in Fig. 1D); values were 6.4, 16.1 and 33.3% (Table 2).3.2.2. Combined dataset
The combined dataset includes the new dataset and the pub-
lished dataset (Aggarwal et al., 2014). Dermal absorption values
from liquid concentrates were 0.6, 1.3 and 5.2% at median, 75th
and 95th percentiles, respectively while corresponding values from
solid concentrates were 0.3, 0.7, and 1.6% (Fig. 2A, Table 2). As for
the previous and the new dataset, the combined dataset shows
higher absorption values for liquid concentrates compared to
solids, especially at the 95th percentile, therefore, separate defaults
of 6% and 2% are proposed for liquids and solids, respectively.
Dermal absorption values from spray dilutions of liquids or
solids were 7.2, 15.8 and 29.9% or 4.6, 9.4 and 27.8% at median,
75th and 95th percentiles, respectively (Fig. 2B, Table 2).
Consistent with the individual datasets, the combined
dataset also showed similar dermal absorption values from spray
dilutions of liquids and solids. Therefore, the data were combined
and resulted in values of 6.7, 15.5 and 31.9% for median, 75th
and 95th percentiles, respectively (Fig. 2B, Table 2). Although, the
95th percentile value for all dilutions in the combined data set
was 31.9%, a single pragmatic default of 30% (which is actually
the 94th percentile) is proposed for all dilutions.3.3. Effect of active substance loading on default values for
concentrates
EFSA GD (2012) has 2 different defaults for concentrates (75%
for concentrations < 5%; otherwise 25%), Therefore, current data
were analysed to see whether active substance loading in the
formulation inﬂuenced dermal absorption.
The inﬂuence of concentration on dermal absorption is
presented in Fig. 3, where datasets (new or combined) are divided
into two groups – one group where active substance concentrate is
<5% and the other with P5% loading. Contrary to EFSA guidance,
dermal absorption from concentrates was not inﬂuenced by con-
centration (Fig. 3A and B). The data indicate that two different
defaults for concentrates based on active substance content are
not justiﬁed.assessment of the combined dataset by physical state with superimposed 95th
Fig. 3. Dermal absorption boxplots of concentrates for new dataset (A) and combined dataset (B) for concentration of active substances (in %) in concentrates with
superimposed 95th percentiles (hollow square).
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Results in Figs. 1 and 2, which are explained in Section 3.2, show
that a formulation matrix could signiﬁcantly inﬂuence dermal
absorption for concentrates but not for spray dilutions. Therefore,
the potential impact that individual formulation type (Fig. 4) and
formulation-type groupings (Fig. 5; organic-solvent basedFig. 4. Dermal absorption of concentrates by formulation type of the new dataset (A) and
formulation types with n > 5 were included for this evaluation.
Fig. 5. Dermal absorption of concentrates of the new dataset (A) and the combined da
percentiles (hollow square). $ represents statistical difference when compared with oth(EC + EW + SE), primarily water based/dispersed (SL + SC + OD
+ FS) and solids (WP +WG + SG)) have on dermal absorption from
concentrates was assessed (Tables 2 and 3).
3.4.1. New dataset
Dermal absorption values from individual formulation types
and groupings of formulations are presented in Figs. 4A and 5A,the combined dataset (B) with superimposed 95th percentiles (hollow square). Only
taset (B) grouped by primary matrix of the formulation with superimposed 95th
er formulation type groupings (⁄).
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higher absorption than other types of formulation, though
replicate (n) for SL types is low compared to EC and SE types of
formulations. However, a greater difference in dermal absorption
is seen between organic-solvent based versus primarily water
based/dispersed formulation or solids (Fig. 5A).
ANOVA found a pronounce statistically signiﬁcant effect of
grouping on dermal absorption (F(2,167) = 18.18, p 0.01,
r = 0.41). Tukey-HSD post hoc analysis (comparing log-means and
not percentiles) revealed signiﬁcant group differences between
organic-solvent based and both primarily water based (p 0.01)
or solid (p 0.01) concentrates; primarily water-based formula-
tions and solids were not signiﬁcantly different (p = 0.41).
All liquids, individually or in grouping, had dermal absorption
values at 95th percentiles of 66% and similarly, solids had <2%
(Figs. 4 and 5, Table 3).
3.4.2. Combined dataset
Dermal absorption values from individual formulation types
and groupings of formulations are presented in Figs. 4B and 5B,
respectively. At 95th percentiles, EC, SE and SL formulations had
similar dermal absorption values though ‘n’ for SL was low
(n = 14; Fig. 5B). Consistent with the new dataset (data not pre-
sented as n was <5) and previous data (Aggarwal et al., 2014),
EW formulations had relatively higher dermal absorption (approxi-
mately 10%) but ‘n’ was small (n = 10; Fig. 4B). As with the new
dataset, the combined dataset also showed considerably higher
dermal absorption from organic-solvent based formulations com-
pared to primarily water based/dispersed or solid formulationsFig. 6. Dermal absorption from spray dilutions by concentration ranges (g/L) for the n
(hollow square).
Table 3
Selected descriptive statistics of dermal absorption values for concentrates grouped
by formulation type for the new and the combined datasets (% dermal absorption).
Number of
values
% Dermal absorption
95th
percentile
75th
percentile
Median
New dataset
EC + EW + SE 61 6.2 2.3 1.1
SL + SC + OD + FS 79 2.3 0.8 0.4
WP +WG + SG 29 1.6 0.8 0.2
Combined dataset
EC + EW + SE 107 6.2 3.0 1.2
SL + SC + OD + FS 135 2.9 0.8 0.4
WP +WG + SG 48 1.7 0.7 0.3(Fig. 5B). However, a strong difference was not observed between
primarily water based/dispersed versus solid formulations (Fig. 5B).
ANOVA found a pronounced statistically signiﬁcant effect of
grouping on dermal absorption (F(2,287) = 36.51, p 0.01,
r = 0.44). Tukey-HSD post hoc analysis (comparing log-means and
not percentiles) revealed signiﬁcant group differences between
organic-solvent based and primarily water-based formulations
(p 0.01) or solids (p 0.01), while primarily water-based and
solid formulations were not signiﬁcantly different (p = 0.85).
All the liquids individually (except EW type) or in groupings
had 66% and similarly solids had <2% dermal absorption values
at 95th percentiles (Figs. 4 and 5; Table 3).3.5. Effect of concentration on dermal absorption from spray dilutions
EFSA GD (2012) requires linear extrapolation (i.e., pro rata cor-
rection) between dermal absorption and concentration in a spray
dilution. Therefore, current data were analysed to see whether
spray dilution concentration inﬂuenced dermal absorption.
The effect of spray dilution concentration on dermal absorption
is presented in Figs. 6 and 7 for both new and combined datasets.
Fig. 6 presents the impact of concentration in 10-fold ranges e.g.,
10–1, 1–0.1, etc. on dermal absorption. As two spray dilutions were
tested in most studies, the impact of change in concentration was
plotted against the fold change in dermal absorption (Fig. 7).3.5.1. New dataset
At 95th percentiles, there was no difference in dermal absorp-
tion between spray dilution ranges of 10–1 versus 1–0.1 versus
0.1–0.01 g/L (Fig. 6A). At medians or 75th percentiles, except for
highly diluted sprays (range 0.01–0.00075 g/L), there was an
increase (though non-linear) in dermal absorption from highly
concentrated spray dilutions (10–187.5 g/L) to less concentrated
dilutions (0.01–0.1 g/L). There is a pronounced drop in dermal
absorption at the lowest concentration range but ‘n’ is only 2
(Fig. 6A).
In the new dataset, there were 93 studies in which two spray
dilutions were tested. As seen graphically (Fig. 7A) this assessment
showed no linear correlation between change in spray concentra-
tion and dermal absorption. The absence of correlation (regression
coefﬁcient 28%) is further conﬁrmed by a line of best ﬁt (polyno-
mial regression: F(5,89) = 8.51, p < 0.01, r2 = 0.32).
With the exception of ﬁve of 93 values, the maximum increase
in dermal absorption was 5-fold, irrespective of the increase in
dilution (Fig. 7A). The ﬁve exceptions were 5.2-, 5.7-, 6.7-, 9.4-ew dataset (A) and the combined dataset (B) with superimposed 95th percentiles
Fig. 7. Change in fold dermal absorption with fold change in dilution factor from new dataset (A, n = 93) and the combined dataset (B, n = 134). The axis was ﬁxed to 50-fold
to allow better assessment and presentation of the data points. Data points with >50-fold change in dermal absorption or dilution factor are not presented. These values are
5.7- and 14.5-fold change in dermal absorption with 108- and 66.7-fold change in dilution factor respectively for the new dataset. Additional value for the combined dataset is
45.6-fold change in dermal absorption from 138.5-fold change in dilution factor.
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13.8- and 66.7-fold increases in dilution factor, respectively.
3.5.2. Combined dataset
Similar results to the new dataset were seen with the combined
dataset (Fig. 7B). In the combined dataset the regression coefﬁcient
was 48%, which conﬁrms the lack of a linear relationship between
dermal absorption and dilution factor.
Only 8 of 136 values exceeded a 5-fold increase in dermal
absorption; these 8 values were 5.2, 5.7, 5.8, 6.7, 9.4, 13, 14.5
and 45.6 from 7.2-, 108- , 20.4-, 15.6-, 13.8-, 16.2-, 66.7- and
138.5-fold increases in dilution factor, respectively. However,
interestingly, the 95th percentile of all dermal absorption fold-
change increases is 5.3, which adds further support to a proposed
default limit of a 5-fold increase in dermal absorption.
Overall, the combined dataset suggests (1) no linear relation-
ship between dilution factor and dermal absorption beyond 5-fold
increases in dilution, (2) the increase in dermal absorption was
typically less than 5-fold.
3.6. Relationship between MW or LogPow and dermal absorption
EFSA Guidance (2012) proposes use of a 10% dermal absorption
default value for an active substance with MW >500 g/mol and
LogPow <1 or >4.3. Out of 108 active substances in this dataset
only 3 (2.8%) meet these criteria. In these 3 studies, dermal absorp-
tion values were 0.6%, 0.8% and 1.0% from the concentrates and
3.8%, 4.6% and 5.7% from the spray dilutions. Graphical analysis
(Fig. 8) does not reveal a relationship between MW or LogPow
and dermal absorption.
4. Discussion
4.1. Comparison of datasets and dermal absorption deﬁnitions
A comparison of the EFSA dataset with the ECPA dataset is pre-
sented in Table 4.
4.1.1. Basing dermal absorption default values on percentiles of
datasets
Dermal absorption is an input parameter in EU regulatory Tier 1
models used to estimate human exposure to active substances foroperators, bystanders, residents and re-entry workers. EFSA’s pro-
posed default dermal absorption values are based on maximum
values from their dataset. The use of maximum values is a highly
conservative option, which is not consistent with human exposure
models and also effectively ignores all other values in the dataset.
It is also interesting to note that the studies used to derive the
maximum values are questioned in the EFSA Scientiﬁc Opinion
(2011) itself: for the 5 active substances with the highest dermal
absorption values for concentrates (18–26%, mainly in rats), EFSA
acknowledged that ‘‘if well performed human in vitro studies had
been available on these products as concentrates, dermal absorption
values lower than those derived by PRAPeR would probably have been
obtained’’. For dilutions, the EFSA dataset contained only 5 values
higher than 30%, and these studies were considered of question-
able quality.
The current regulatory proposal for non-dietary human expo-
sure assessments is to use descriptive statistics of the assessed data
packages, e.g., the 75th percentile of the exposure data distribution
for sub-chronic exposure scenarios, which has been accepted in the
EU for decades, and the 95th percentile for acute exposures (EFSA,
2010, 2014). The ‘German model’ for operator exposure assess-
ment (BBA, 1992) uses geometric means to provide better control
of outliers compared to 75th percentiles. From a scientiﬁc perspec-
tive, it would be logical to align default dermal absorption values
with the corresponding EFSA human exposure defaults by using
the 75th and 95th percentile values for short-term and acute sce-
narios, respectively. However, a more pragmatic and conservative
option that would reduce the number of default values would be
to use the 95th percentile of dermal absorption for both acute
and repeated exposure scenarios. Therefore, the worst-case of
these options (i.e., the 95th percentile) was applied to dermal
absorption endpoints in this review, which is also consistent with
EFSA’s guidance ‘‘Where science is equivocal or lacking, existing
practises and/or recommendations in other regulations/guidance
documents are proposed to be followed’’ (EFSA, 2012).
While some empirical in vitro human dermal absorption values
for some formulation concentrates and spray dilutions might
exceed proposed defaults calculated by the proposed approach,
such exceptions would be rare, would certainly exceed real-life
in vivo values and would be mitigated by the numerous conser-
vatisms already built into the overall EFSA risk characterisation
process, including the calculation of the proposed default values.
Fig. 8. Dermal absorption of concentrates (A, B) and their spray dilutions (C, D) by molecular weight (A, C) or LogPow (B, D). Values of the new dataset are depicted by hollow
circles while data of the previous assessment (Aggarwal et al., 2014) are shown by solid triangles.
Table 4
Major differences between EFSA and ECPA datasets.
Attribute EFSA dataset ECPA combined dataset
Study type Variablea) – in vitro rat and human, in vivo rat and
monkey, triple-pack, default, expert judgment, etc.
Homogeneous – in vitro human skin only, as preferred by EU Regulation for
PPP
GLP and OECD TG compliance Not reported All studies are GLP and OECD TG 428 compliant
Exposure and study duration Not reported 6–10 h exposure period with total study duration of 24 h
Method of dermal absorption
calculation
Variable – with regards to the skin residue and
correction factor that was used for triple-pack
studies
Consistent – all dermal absorption calculations are based on EFSA guidance
worst-case option assuming skin residue (except ﬁrst 2 tape strips) is
absorbedb
Number of active substances 63 152
Number of studies Not reported 295
Number of dermal absorption
values
Approximately 63 for concentrates and 63 for
dilutions
303 for concentrates and 446 for dilutions
a Of the endpoints used for analysis, 3% are default values,14% are for human skin in vitro,9% are for human and rat skin in vitro,26%/5% are in vivo rat/monkey, and
30% are ‘‘triple pack’’.
b Dermal absorption = radioactivity present in receptor ﬂuid + receptor chamber wash + whole skin sample – radioactivity in the ﬁrst two tape strips of the stratum
corneum.
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Regarding dermal absorption deﬁnitions, OECD considers an
absorbed dose as the ‘‘mass of test substance reaching the receptor
ﬂuid or systemic circulation within a speciﬁed period of time’’
(OECD 428, 2004). This OECD deﬁnition is supported by a recent
review that compared 92 datasets of human in vivo and in vitro
dermal absorption data (Lehman et al., 2011). When the absorbed
dose in human volunteers was compared to corresponding recep-
tor ﬂuid values from in vitro studies with human skin, the mean
in vitro to in vivo ratio for the entire dataset was 1.6, and for theeleven harmonised studies, the correlation was almost perfect
(0.96).
For regulatory purposes, it would be reasonable and con-
servative to assume the in vitro residue in the vascular dermis as
absorbed, even though it had not diffused into the receptor ﬂuid
by the end of a 24-h experimental period. However, the epidermis,
including the stratum corneum, is non-vascular and its cells divide
and grow in an outward direction, eliminating any retained residue
over time via desquamation. Different regulatory guidance
includes different skin layers in the absorbed dose, for example,
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residue in the stratum corneum (SCCS, 2010).
The weight of evidence provides little to no doubt that a residue
in the stratum corneum at the end of a 24-h experimental period
should be excluded from the estimation of an absorbed dose.
This option is readily achievable for PPP as most if not all of the
stratum corneum residue is determined in standard in vitro studies
by comprehensive tape stripping. This could make a signiﬁcant dif-
ference to the calculation of an absorbed dose; for example, 22.7%
versus 28.0% for the 95th percentile values for diluted PPPs
(Aggarwal et al., 2014).
EFSA guidance (EFSA, 2012) allows for this approach but only
when 75% of the estimated absorption is represented by the recep-
tor ﬂuid value by 12 h of a 24-h study. However, based on the
OECD recommendation (OECD 428, 2004), the comparative data
of Lehman et al. (2011), the SCCS approach (SCCS, 2010), and the
highly conservative assumption that the rest of the epidermal
(and dermal) residue remaining after 24 h of testing is absorbed,
exclusion of the entire stratum corneum should become the default
approach for PPP.
Until recently, epidermis and dermis were not analysed sepa-
rately in regulatory studies. However, exclusion of the residue in
the entire epidermis should potentially be the default approach
in future, especially as measurement of epidermis separately is
starting to become a component of in vitro dermal absorption stud-
ies. This option would provide the most relevant value for use in
risk assessments for PPP, while still remaining acceptably
conservative.
That said, for expediency and to increase the opportunity for
reﬁnement of current regulatory criteria (EFSA, 2012) this review
adopted the most conservative approach of using EFSA’s worst-
case deﬁnition: Dermal absorption = [Radioactivity present in
receptor ﬂuid + receptor chamber wash + whole skin sam-
ple]  [radioactivity in the ﬁrst two tape strips].
An initial assessment (data not presented) of the new and
combined dataset indicated that approximately half of the result-
ing dermal absorption values derived by this method have more
than 50% of the ‘absorbed dose’ in the skin at the end of the experi-
mental period. Interestingly, those compounds showing high skin
residues and thus impacting the dermal absorption estimates
according to EFSA’s worst-case deﬁnition coincide with low pene-
trations into the receptor compartment (data not shown). This
underlines the conservatism of the assessment presented in this
review. It also highlights the possibility of developing a ‘skin
residue factor’ for reﬁning estimates of dermal absorption for sub-
stances with high skin residues and low penetration through to the
receptor ﬂuid, as a separate project.
4.2. Default dermal absorption values
4.2.1. Defaults for concentrates
303 dermal absorption values for concentrates were assessed
(Figure 2A, Table 2). As all studies in this review were OECD GLP
and test guideline-compliant, of one type and the number of obser-
vations was very high in comparison with the EFSA dataset
(Table 4) they are considered to be sufﬁciently robust to derive
reliable and deﬁnitive conclusions. Results show that dermal
absorption from liquid concentrates was, as expected, higher than
solid concentrates. Therefore, two different default values are pro-
posed for concentrates: 6% for liquid and 2% for solid concentrates.
These defaults are in agreement with previously proposed values
(Aggarwal et al., 2014).
4.2.1.1. Impact of active substance concentration on dermal
absorption. EFSA guidance contains two different default values
for concentrates depending on concentration of the activesubstance in the concentrate. The current analysis shows no
relationship between dermal absorption and the level of active
substance in a concentrate (Fig. 3). This ﬁnding is consistent with
the previous assessment (Aggarwal et al., 2014).
Based on the current dataset, overall defaults of 6% for liquids
and 2% for solids are proposed and are independent of the level
of active substance in a concentrate.
4.2.2. Default values for spray dilutions
446 dermal absorption values for a broad range of dilutions
were assessed (Figs. 1D and 2B; Table 2). Dermal absorption from
dilutions of liquids and solids were similar and support a single
default value. The 95th percentile of all dilutions (n = 446) was
31.9%. As described in Section 3.1, some of the highest dermal
absorption values appeared to be outliers but a deﬁnitive rationale
for exclusion could not be established. As a precautionary
approach, these values were retained, but if they had been
excluded, the 95th percentile would have been 30%, which actually
represents the 94th percentile of the combined dataset. Therefore,
a reasonable and pragmatic default of 30% is proposed for all dilu-
tions, which is in line with the previous assessment (Aggarwal
et al., 2014).
4.3. Read-across between formulation types for concentrates
To understand which formulation type(s) would give generi-
cally higher dermal absorption values, data from different types
were grouped into broad classes of: organic solvent-based (EC,
EW, SE), primarily water based/dispersed (SL, SC, OD, FS) and solids
(WP, WG, SG).
EC + EW + SE formulations had higher 95th percentile values
than other evaluated formulation types. This is likely due to the
fact that most of the active substances in EC, EW and SE are solu-
bilised in the organic solvent and are immediately available for
dermal penetration, while in all other formulation types (except
SL) active substances are only partly dissolved. Dermal absorption
from the organic solvent-based formulations was, as expected,
higher than those of primarily water-based/dispersed types or
solids (Fig. 5). Contrary to the previous assessment (Aggarwal
et al., 2014) there was no appreciable difference between absorp-
tion from primarily water based/dispersed versus solids, probably
because most of the solids were tested as pastes in 1:1 or higher
dilutions. Therefore, dermal absorption data generated with a sol-
vent-based formulation could be used as conservative surrogates
for primarily water-based/dispersed and solid formulations.
Similarly, dermal absorption data generated with primarily
water-based/dispersed formulations could be used for solid
formulations.
Fig. 4B suggests that EW products have higher absorption than
EC formulations, and SL are similar to EC types but ‘n’ for EW and
SL are relatively low (10 and 14, respectively) compared to ECs
(n = 67) to make a ﬁrm conclusion. On a weight of evidence, EC
type formulations can be considered as conservative surrogates
for read-across for all but EW formulations.
4.4. Impact of dilution on dermal absorption
In a gross analysis, dermal absorptionwas low for both extremes
of spray concentrations (>10 or <0.01 g/L) however, at concentra-
tion between 10 to 0.01 g/L, absorption was stable at 95th per-
centile or median levels but a non-linearly increasing trend was
apparent for the 75th percentiles (Fig 6). Therefore, a higher-tier
analysis was performed for studies where two spray dilutions were
tested (134 studies; Fig. 7B). Results showed dermal absorption
increasedwith dilution but not in a linear fashion. For the combined
dataset, the 95th percentile of fold-increase in dermal absorption
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ies the increase in dermal absorption was <5 irrespective of fold
change in dilution (Section 3.5.2). These 8 studies also did not show
linear change in absorption with dilution and absorption values
were below the proposed defaults of 30% for sprays (5–28%). A poly-
nomial regression ﬁt for the combined data had a much lower
coefﬁcient than the previous assessment (0.50 versus 0.95;
Aggarwal et al., 2014). Re-evaluation of the previous data revealed
two inﬂuential observations, with a high leverage, identiﬁed by
graphical analysis of the previous regression model (residual vs
leverage plot). One of the two values, a FS formulation with a dilu-
tion factor of 138 and a fold change of 46, was already identiﬁed as
an outlier in the previous publication but was included in the
model. The second value was an OD formulationwith a dilution fac-
tor of 36 and absorption fold change of 3. When these values were
excluded from the model ﬁt based on their Cook’s distance (Cook,
1977) the regression coefﬁcient dropped to 0.16.
When a similar approach was applied to the new dataset, three
inﬂuential observations were identiﬁed, one WP formulation with
a dilution factor of 67 and absorption fold change of 14 and two SL
formulations with dilution factors of 630 and 650 and fold changes
of 3. Excluding those values from the model for the new data
resulted in a coefﬁcient of determination of 0.19, low and com-
parable to the previous dataset. When those studies are excluded
from the ﬁt of the combined dataset, the regression coefﬁcient
was reduced to 0.39. The regression coefﬁcient values for simple
linear regressions are even lower; hence no linear dose–response
relationship could be statistically established for dermal absorp-
tion fold change and dilution factor.
The results showed that most dermal absorption increases with
dilution were considerably smaller than predicted by a pro rata
approach (Fig. 7). Therefore, a pro rata adjustment, as proposed
by EFSA guidance (EFSA, 2012) is not a correct approach for
estimating dermal absorption for a dilute spray. Therefore, based
on these results and in agreement with the previous conclusion
(Aggarwal et al., 2014), the authors propose the following steps
to extrapolate dermal absorption for untested dilutions:
Step 1 If there is no remarkable difference in available dermal
absorption data for 2 or more spray dilutions, there is no
need to test a new dilution. If there is a remarkable differ-
ence, follow Steps 2 and 3.
Step 2 If the new dilution is 62-fold the lowest concentration
tested, there is no need to adjust the untested new dilution
(Niemann et al., 2013).
Step 3 If the new spray >2-fold more dilute than the lowest con-
centration tested, a pro-rated correction is applied up to a
5-fold difference or the 30% default dermal absorption is
reached, whichever is lower.
4.5. Relationship between MW or LogPow and dermal absorption
EFSA guidance (EFSA, 2012) proposed use of a 10% dermal
absorption default value for an active substance with MW >500
and LogPow <1 or >+4 (Table 2). In the current dataset (Fig. 8) only
3 of 108 active substances met these physico-chemical criteria, and
dermal absorption was <1% and <6% for concentrates and spray
dilutions, respectively. Therefore, a separate default value for con-
centrates based on MW or LogPow is not required.
4.6. General considerations on the EFSA guidance document
The current EFSA guidance is a comprehensive document
designed to give a broad and detailed overview on how to evaluate
dermal absorption data for agrochemicals and to provide consis-
tent outcomes across Member State agencies. While this is anunderstandable and laudable objective, expert judgement should
always be an integral part of data evaluation to avoid irrelevant
outcomes for human risk assessments. It might seem acceptable
to consistently over-estimate dermal absorption and thus provide
highly conservative risk assessments but there must be a reason-
able balance between conservatism and reliability to avoid giving
a false impression of danger associated with exposure to
chemicals, including PPP. Examples of how the balance has been
distorted beyond reasonable levels are summarised below.
4.6.1. Conservatisms associated with dermal absorption calculations
Conservatisms, including some in the EFSA GD, that result in
signiﬁcant over-predictions for dermal absorption include:
1. Considering the entire skin residue, except for the ﬁrst 2 tape
strips of the stratum corneum, to be absorbed, even though
absorption (e.g., into the receptor ﬂuid) has not occurred by
the end of the test period;
2. Solids per se cannot be absorbed, but all solid concentrates are
tested as an aqueous paste or applied to wet skin, inevitably
overestimating real-life absorption: EFSA Scientiﬁc Opinion
(2011, based on Gordon and Leon, 2005) acknowledges that
sweat might increase the overall magnitude of dermal absorp-
tion of solids, but less than 2-fold and that good hygienic prac-
tices after contamination could be reasonably assumed.
3. Dermal absorption studies have 6–10 h exposure periods
compared with the actual duration of mixing and loading pro-
cedures (e.g., less than 1 h/day for handling undiluted product).
It can also be reasonably assumed that splashes to skin would
be washed-off by the operator at the time of contamination
(also see #2). Exposure times of 6–10 h used in dermal absorp-
tion studies are signiﬁcantly longer than exposure periods
assumed for bystander and resident risk scenarios. Even for
applicators, exposure to spray occurs throughout a working
day, not all at once at the beginning, as is the case in a dermal
absorption study that therefore exaggerates the time available
for absorption to occur.
4. Standard deviation – EFSA guidance requires addition of stan-
dard deviation (SD) to the mean when SD is above 25% of the
mean, even though a high number of replicates (n = 6 to 8)
are routinely used. SD is often > 25% of the mean when absorp-
tion is low and in some cases, adding the SD to the mean actu-
ally exceeds the maximum absorption value for any individual
replicate. Moreover, no OECD TG, including OECD TG 428 or
any other in vitro test, requires this approach.
5. Recovery (or mass balance) – EFSA guidance requires recovery
of <95% to be added or normalised to the absorption value.
This is not required by OECD for dermal absorption studies
(OECD 427, 2004; OECD 428, 2004; OECD 156, 2011) or for
toxicokinetics (OECD 417, 2010) which all accept a recovery
range of 100 ± 10%. Recovery mainly depends upon the speciﬁc
activity of the radiolabelled compound, concentration tested
and absorption proﬁle. Achieving recovery exceeding 95% is
technically very challenging, for example when speciﬁc activity
is low, testing of spray dilutions at very low concentrations and
when absorbed through skin is low.
4.6.2. Read-across – use of existing data for a similar formulation
Under the current EFSA guidance it is practically impossible to
use existing data from a similar formulation for the following
reasons.
4.6.2.1. 25% change to a co-formulant level. To qualify for equiva-
lence between formulations EFSA guidance (Section 1.1) requires:
‘‘Co-formulant (e.g. solvent, stabiliser, surfactant, detergent emulsiﬁer,
adhesive, anti-freezing substance) content is within ±25% w/w of that
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co-formulant both in the undiluted product and in use spray dilu-
tions and often makes read-across impossible. Literal application of
this rule creates ridiculous but real examples of where of the guid-
ance prevents read-across. Examples that unnecessarily trigger
new studies include: a small change in any co-formulant with
low content (e.g., less than 10%) readily exceeds the 25% change
criteria, such as anti-freeze increasing from 5% to 6.5%, which is a
+30% change preventing read-across and triggering a new study;
any new co-formulant immediately negates read-across such as a
dispersant or biocide that would not impact dermal absorption; a
decrease in a co-formulant should not increase dermal absorption;
and so forth.
While signiﬁcant increases in some co-formulants, such as
solvents, adjuvants, detergents, emulsiﬁers, might impact the phy-
sico-chemical properties of the active substance and hence dermal
absorption, this is not the intension for other inert co-formulants
such as thickeners, antifreeze and biocides. Comparisons should
also take account of critical co-formulants, such as solvent in an
EC formulation, by comparing solvent:active substance ratios;
any change exceeding 25% would trigger a new study. Overall, if
the changes in total co-formulants exceeded +25% of the tested
PPP this would be a more sensible trigger for a new study, but this
should be limited to the concentrate as the spray dilution repre-
sents mainly water and our data indicate that formulation type
does not inﬂuence absorption of dilutions.4.6.2.2. Skin irritation and skin sensitisation. The consideration that
skin irritation and skin sensitisation may alter the skin barrier
and thus impact dermal absorption is in principle plausible for
concentrates. Spray dilutions are typically far too dilute
(Tominack, 2000) to cause skin irritation or sensitisation, and
exceptions are usually known.
According to a Denmark EPA review (2009) dermal absorption
of highly lipophilic compounds could be affected by an irritant/
sensitiser but not for hydrophilic compounds. ‘‘Damage of the skin
barrier integrity by SLS has previously been attributed to removal of
intercellular hydrophilic lipids, which may be observed through an
increase in TEWL. (Froebe et al., 1990). A later study has indicated that
SLS ﬂuidizes the lipid bilayers in the stratum corneum (Ribaud et al.,
1994). These two effects are suggested to increase percutaneous pene-
tration of primarily hydrophilic compounds (Akomeah et al., 2007,
2008), whereas the percutaneous penetration of highly lipophilic com-
pounds should remain unaffected (Borras-Blasco et al., 2004).’’
Additionally, skin reactions like erythema or oedema are absent
in excised skin in vitro therefore impact on dermal absorption is
not feasible. It should also be taken into account that the dermal
loading in skin irritation studies is 8-fold higher than in dermal
absorption studies (80 ll/cm2 versus 10 ll/cm2) and thus the
impact (if any) would be further reduced in an in vitro dermal
absorption study. Also, skin sensitisation is equally irrelevant to
an in vitro dermal absorption system. Furthermore, and on a prac-
tical level, if a particular PPP caused sensitisation in an individual
worker, they need to ensure that they either wear appropriate per-
sonal protective equipment as described on the product label, or
stop using the product to avoid further skin sensitisation.5. Conclusions
This analysis was carried out using a combination of the EFSA
worst-case option for dermal absorption (i.e., skin residue except
ﬁrst 2 tape strips is absorbed) and 95th percentile values of the
datasets. The analysis supported (1) defaults of 6% for liquid and
2% for solid concentrates irrespective of the active substance load-
ing, (2) a single default of 30% for all spray dilutions irrespective offormulation type, (3) solvent-based formulations (EC type) as
conservative surrogates for read-across for primarily water
based/dispersed and solid formulations, similarly, dermal absorp-
tion values derived from primarily water-based/dispersed
formulations can be used as a read-across for solids, (4) absorption
not increasing linearly with dilution; rather there should be no
adjustment for a <2-fold change, a linear increase between 2 to
5-fold or use of a default of 30% and (5) stratum corneum not being
considered part of an absorbed dose. This assessment also vali-
dated conclusions from the previous dataset (Aggarwal et al.,
2014).
The data demonstrate that EFSA’s default values and other cri-
teria are not supported when larger and more consistent datasets
are analysed. The combined dataset provides compelling evidence
for revision of the EFSA guidance.Conﬂict of interest statement
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